Building the Next Generation
of Precision Oncology Therapeutics
A selective precision oncology platform integrating inhibition and targeted degradation.
Alaw Therapeutics is a biotechnology company developing precision oncology therapeutics designed to control oncogenic proliferation, tumor survival, and therapeutic resistance through highly selective small molecules and next-generation targeted degradation approaches. Our programs are engineered to address aggressive tumor biology where conventional therapies may be limited by resistance mechanisms, inadequate CNS exposure, or off-target toxicity.
Founded in 2024, Alaw Therapeutics is advancing a pipeline of selective precision oncology programs, including AL-605, a selective brain-penetrant CDK2 inhibitor, AL-433, a selective brain-penetrant CDK4 inhibitor, and next-generation RIPTAC therapeutics designed for tumor-selective pathway control.
Investors
Selective. Programmable. AI-Driven.
-
We develop highly selective precision therapeutics designed to control oncogenic signaling while minimizing off-target activity and expanding the therapeutic window across resistant and aggressive cancers.
-
Our platform integrates selective small molecules and next-generation targeted degradation approaches to enable programmable control of tumor proliferation, survival, and adaptive signaling pathways.
-
Alaw integrates proprietary data, 3D/4D hybrid machine-learning models, docking, virtual screening, scaffold hopping, and ADMET modeling to accelerate rational drug design.
